3 Things You Didn’t Know About bluebird bio, Inc. – Motley Fool
Motley Fool |
3 Things You Didn’t Know About bluebird bio, Inc.
Motley Fool Most investors are rightfully focused on Bluebird’s LentiGlobin gene therapy treatment. It offers nice potential in the orphan indication of beta thalassemia, plus a more lucrative indication in sickle-cell disease. But there’s a gene–therapy product … |
Targeted Oncology |
Expert Reflects on Immunotherapy’s Milestone Impact in NSCLC, and Questions That Still Remain
Targeted Oncology Immunotherapy has made a significant impact in the field of non–small cell lung cancer (NSCLC). However, as more research unravels, investigators are unsure which set of combinations will have the most positive effect on their patients with advanced … |
Targeted Oncology |
Expert Reflects on Immunotherapy’s Milestone Impact in NSCLC, and Questions That Still Remain
Targeted Oncology Immunotherapy has made a significant impact in the field of non–small cell lung cancer (NSCLC). However, as more research unravels, investigators are unsure which set of combinations will have the most positive effect on their patients with advanced … |
OncLive |
Expert Discusses Immunotherapy Advances in Head and Neck Cancer
OncLive “Regarding the responsiveness of immunotherapy versus the responsiveness of standard-of-care chemotherapy, platinum-based doublets with cetuximab have response rates of 40% and PD-1 inhibitors have response rates of 18%. For symptomatic patients … |
Genetic Engineering & Biotechnology News |
Scaffold Delivers ‘Atomic Bomb’ CAR–T Tx in Preclinical Solid Tumors
MedPage Today A tiny implantable biopolymer scaffold that delivers rapidly-expanding densities of anti-tumor chimeric antigen receptor (CAR) T-cells as well as immune-boosting beta-agonists to either the surface of a tumor or to the resection site in the preclinical … Anticancer T Cells Occupy Biopolymer Camp Sites in the Solid Tumor WildGenetic Engineering & Biotechnology News Fred Hutch Study: Novel immunotherapy tech made tumors shrink, a good sign for future treatmentsGeekWire Dissolving implant could bring immunotherapy to solid tumorsFred Hutch News Service |